Literature DB >> 33844319

Tumor cell heterogeneity and its transcriptional bases in pancreatic cancer: a tale of two cell types and their many variants.

Marta Milan1, Giuseppe R Diaferia1, Gioacchino Natoli1,2.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC), one of the most highly lethal tumors, is characterized by complex histology, with a massive fibrotic stroma in which both pseudo-glandular structures and compact nests of abnormally differentiated tumor cells are embedded, in different proportions and with different mutual relationships in space. This complexity and the heterogeneity of the tumor component have hindered the development of a broadly accepted, clinically actionable classification of PDACs, either on a morphological or a molecular basis. Here, we discuss evidence suggesting that such heterogeneity can to a large extent, albeit not exclusively, be traced back to two main classes of PDAC cells that commonly coexist in the same tumor: cells that maintained their ability to differentiate toward endodermal, mucin-producing epithelia and epithelial cells unable to form glandular structures and instead characterized by various levels of squamous differentiation and the expression of mesenchymal lineage genes. The underlying gene regulatory networks and how they are controlled by distinct transcription factors, as well as the practical implications of these two different populations of tumor cells, are discussed.
© 2021 The Authors.

Entities:  

Keywords:  differentiation; pancreatic cancer; pancreatic ductal adenocarcinoma; transcription; tumor grading

Mesh:

Substances:

Year:  2021        PMID: 33844319      PMCID: PMC8246061          DOI: 10.15252/embj.2020107206

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   14.012


  93 in total

Review 1.  Molecular subtypes of pancreatic cancer.

Authors:  Eric A Collisson; Peter Bailey; David K Chang; Andrew V Biankin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-04       Impact factor: 46.802

2.  Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

Authors:  Dung T Le; Andrea Wang-Gillam; Vincent Picozzi; Tim F Greten; Todd Crocenzi; Gregory Springett; Michael Morse; Herbert Zeh; Deirdre Cohen; Robert L Fine; Beth Onners; Jennifer N Uram; Daniel A Laheru; Eric R Lutz; Sara Solt; Aimee Luck Murphy; Justin Skoble; Ed Lemmens; John Grous; Thomas Dubensky; Dirk G Brockstedt; Elizabeth M Jaffee
Journal:  J Clin Oncol       Date:  2015-01-12       Impact factor: 44.544

3.  Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study).

Authors:  Dung T Le; Vincent J Picozzi; Andrew H Ko; Zev A Wainberg; Hedy Kindler; Andrea Wang-Gillam; Paul Oberstein; Michael A Morse; Herbert J Zeh; Colin Weekes; Tony Reid; Erkut Borazanci; Todd Crocenzi; Noelle K LoConte; Benjamin Musher; Dan Laheru; Aimee Murphy; Chan Whiting; Nitya Nair; Amanda Enstrom; Sandy Ferber; Dirk G Brockstedt; Elizabeth M Jaffee
Journal:  Clin Cancer Res       Date:  2019-05-24       Impact factor: 12.531

Review 4.  Pancreatic cancer.

Authors:  Jorg Kleeff; Murray Korc; Minoti Apte; Carlo La Vecchia; Colin D Johnson; Andrew V Biankin; Rachel E Neale; Margaret Tempero; David A Tuveson; Ralph H Hruban; John P Neoptolemos
Journal:  Nat Rev Dis Primers       Date:  2016-04-21       Impact factor: 52.329

5.  Lack of TCF2/vHNF1 in mice leads to pancreas agenesis.

Authors:  C Haumaitre; E Barbacci; M Jenny; M O Ott; G Gradwohl; S Cereghini
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-24       Impact factor: 11.205

6.  The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice.

Authors:  Paola Martinelli; Francesc Madriles; Marta Cañamero; Enrique Carrillo-de Santa Pau; Natalia Del Pozo; Carmen Guerra; Francisco X Real
Journal:  Gut       Date:  2015-01-16       Impact factor: 23.059

7.  Hnf1b controls pancreas morphogenesis and the generation of Ngn3+ endocrine progenitors.

Authors:  Matias G De Vas; Janel L Kopp; Claire Heliot; Maike Sander; Silvia Cereghini; Cécile Haumaitre
Journal:  Development       Date:  2015-03-01       Impact factor: 6.868

8.  RAB26 and RAB3D are direct transcriptional targets of MIST1 that regulate exocrine granule maturation.

Authors:  Xiaolin Tian; Ramon U Jin; Andrew J Bredemeyer; Edward J Oates; Katarzyna M Błazewska; Charles E McKenna; Jason C Mills
Journal:  Mol Cell Biol       Date:  2009-12-28       Impact factor: 4.272

9.  The formation and maintenance of the definitive endoderm lineage in the mouse: involvement of HNF3/forkhead proteins.

Authors:  S L Ang; A Wierda; D Wong; K A Stevens; S Cascio; J Rossant; K S Zaret
Journal:  Development       Date:  1993-12       Impact factor: 6.868

10.  Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer.

Authors:  Rémy Nicolle; Yuna Blum; Pauline Duconseil; Charles Vanbrugghe; Nicolas Brandone; Flora Poizat; Julie Roques; Martin Bigonnet; Odile Gayet; Marion Rubis; Nabila Elarouci; Lucile Armenoult; Mira Ayadi; Aurélien de Reyniès; Marc Giovannini; Philippe Grandval; Stephane Garcia; Cindy Canivet; Jérôme Cros; Barbara Bournet; Louis Buscail; Vincent Moutardier; Marine Gilabert; Juan Iovanna; Nelson Dusetti
Journal:  EBioMedicine       Date:  2020-07-03       Impact factor: 8.143

View more
  6 in total

Review 1.  The multifaceted role of autophagy in cancer.

Authors:  Ryan C Russell; Kun-Liang Guan
Journal:  EMBO J       Date:  2022-05-10       Impact factor: 14.012

Review 2.  Cancer evolution: Darwin and beyond.

Authors:  Roberto Vendramin; Kevin Litchfield; Charles Swanton
Journal:  EMBO J       Date:  2021-08-30       Impact factor: 14.012

Review 3.  Tumor cell heterogeneity and its transcriptional bases in pancreatic cancer: a tale of two cell types and their many variants.

Authors:  Marta Milan; Giuseppe R Diaferia; Gioacchino Natoli
Journal:  EMBO J       Date:  2021-04-12       Impact factor: 14.012

Review 4.  Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy.

Authors:  Martijn A van Dam; Floris A Vuijk; Judith A Stibbe; Ruben D Houvast; Saskia A C Luelmo; Stijn Crobach; Shirin Shahbazi Feshtali; Lioe-Fee de Geus-Oei; Bert A Bonsing; Cornelis F M Sier; Peter J K Kuppen; Rutger-Jan Swijnenburg; Albert D Windhorst; Jacobus Burggraaf; Alexander L Vahrmeijer; J Sven D Mieog
Journal:  Cancers (Basel)       Date:  2021-12-02       Impact factor: 6.639

Review 5.  Crosstalk between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance.

Authors:  Enrique Rozengurt; Guido Eibl
Journal:  Cancers (Basel)       Date:  2021-10-13       Impact factor: 6.639

6.  On the molecular, cellular and tissue origin of cancer.

Authors:  Elisabetta Argenzio; Daniel Klimmeck
Journal:  EMBO J       Date:  2021-07-21       Impact factor: 14.012

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.